[go: up one dir, main page]

IL130599A0 - Use of angiotensin II antagonists to treat symptomatic heart failure - Google Patents

Use of angiotensin II antagonists to treat symptomatic heart failure

Info

Publication number
IL130599A0
IL130599A0 IL13059998A IL13059998A IL130599A0 IL 130599 A0 IL130599 A0 IL 130599A0 IL 13059998 A IL13059998 A IL 13059998A IL 13059998 A IL13059998 A IL 13059998A IL 130599 A0 IL130599 A0 IL 130599A0
Authority
IL
Israel
Prior art keywords
heart failure
angiotensin
symptomatic heart
antagonists
treat symptomatic
Prior art date
Application number
IL13059998A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704197.4A external-priority patent/GB9704197D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL130599A0 publication Critical patent/IL130599A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
IL13059998A 1997-01-10 1998-01-07 Use of angiotensin II antagonists to treat symptomatic heart failure IL130599A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3492797P 1997-01-10 1997-01-10
GBGB9704197.4A GB9704197D0 (en) 1997-02-28 1997-02-28 Method for reducing mortality with an angiotensin 11 antagonist
PCT/US1998/000534 WO1998030216A1 (en) 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure

Publications (1)

Publication Number Publication Date
IL130599A0 true IL130599A0 (en) 2000-06-01

Family

ID=26311085

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13059998A IL130599A0 (en) 1997-01-10 1998-01-07 Use of angiotensin II antagonists to treat symptomatic heart failure

Country Status (18)

Country Link
EP (1) EP0966282B1 (xx)
JP (1) JP2000508347A (xx)
KR (1) KR20000070046A (xx)
CN (1) CN1249682A (xx)
AT (1) ATE243515T1 (xx)
AU (1) AU729881B2 (xx)
CA (1) CA2277018C (xx)
DE (1) DE69815822T2 (xx)
DK (1) DK0966282T3 (xx)
EA (1) EA199900635A1 (xx)
EE (1) EE9900278A (xx)
ES (1) ES2200310T3 (xx)
HU (1) HUP0000108A2 (xx)
IL (1) IL130599A0 (xx)
NO (1) NO993399L (xx)
PT (1) PT966282E (xx)
SK (1) SK92899A3 (xx)
WO (1) WO1998030216A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
NZ517468A (en) 1999-08-30 2004-02-27 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
RS65037B1 (sr) * 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
CA3029630A1 (en) 2016-06-29 2018-01-04 Universite De Montreal Biarylmethyl heterocycles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9609066A (pt) * 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração

Also Published As

Publication number Publication date
JP2000508347A (ja) 2000-07-04
WO1998030216A1 (en) 1998-07-16
DE69815822D1 (de) 2003-07-31
CA2277018C (en) 2006-10-03
SK92899A3 (en) 2000-08-14
ES2200310T3 (es) 2004-03-01
EA199900635A1 (ru) 2000-02-28
DE69815822T2 (de) 2004-05-06
EE9900278A (et) 2000-02-15
DK0966282T3 (da) 2003-09-29
EP0966282A1 (en) 1999-12-29
ATE243515T1 (de) 2003-07-15
CN1249682A (zh) 2000-04-05
HUP0000108A2 (hu) 2001-04-28
AU729881B2 (en) 2001-02-15
AU6021898A (en) 1998-08-03
CA2277018A1 (en) 1998-07-16
NO993399L (no) 1999-09-09
NO993399D0 (no) 1999-07-09
KR20000070046A (ko) 2000-11-25
PT966282E (pt) 2003-10-31
EP0966282B1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
EA200100418A1 (ru) Комбинированная терапия с применением ингибитора фермента конверсии ангиотензина и антагониста альдостерона для снижения заболеваемости и смертности при сердечно-сосудистых заболеваниях
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
BR9609066A (pt) Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
NZ514077A (en) Treatment of Α-galactosidase A deficiency
AP2000001785A0 (en) Medicaments
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DE69814394D1 (de) Verwendung von levobupivacain
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
IL130599A0 (en) Use of angiotensin II antagonists to treat symptomatic heart failure
AU9058591A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
IL132853A0 (en) Combination therapy for modulating the human sexual response
TR199701536T1 (xx) Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�.
WO1993020839A3 (en) Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
CA2091134A1 (en) Therapeutic agent for threatened abortion
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
ES2166816T3 (es) Derivados piridil-imidazolicos y procedimientos para su preparacion.
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
SE8902458L (sv) Laekemedelskomposition
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
MD980129A (en) Antiherpetic remedy
MX9707939A (es) Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
JPS6485990A (en) Antihypertestoeronemia agent
AR021106A1 (es) Terapia combinada de un inhibidor de la enzima convertidora de angiotensina y un antagonista de aldosterona para reducir la morbilidad y mortalidad porenfermedades cardiovasculares